The pharmaceutical company Farmak has supplemented its portfolio with a new brand – hepatic medicine Hep-Art. The drug is available as a lyophilisate solution for injection.
The new product of Farmak – Hep-Art contains an active substance ademetionine.
Ademetionine deficiency plays a key role in the hepatopathy. Reduced ademetionine level deteriorates the liver condition leading to inflammation and further to irreversible structural and degenerative changes in the liver.* Hep-Art eliminates deficiency of the endogenous ademetionine and stimulates its production in the body.
According to the instructions, it is indicated to treat:
intrahepatic cholestasis in adults, including patients with chronic hepatitis of various etiologies and cirrhosis; intrahepatic cholestasis of pregnancy; depressive syndromes.
Olga Vereshchaka, Farmak Product Manager, "Hep-Art helps to restore the liver. Hep-Art acts as an antioxidant; it regenerates hepatic cells, and improves bile production and outflow. The triple action determines 7 effects of Hep-Art: choleretic, cholekinetic, antioxidant, detoxification, regeneration, neuroprotective,** antidepressant. Thus, we are able to treat patients with the intrahepatic cholestasis syndrome, getting improvement in their condition."
The drug is sold by prescription only.
Training will start for more than 100 students who have signed up, and every student wishing to attend training sessions may join them. While attending the Eco-School, the students will gain the current knowledge about energy saving, climate changes, biodiversity, and interrelations in nature through the tabletop and active environmental games. They w...
According to “Business” magazine, JSC “Farmak” is ranked among the TOP 5 companies of Ukraine in the nomination “Strong Top Management – Dream Team”. The foundation of strong and modern business is its staff component. People, their development, professionalism are the core values of “Farmak”. “We have more than 2500 employees. We fill more than […]
According to the decision of economic courts of all instances (2009-2010), the name “Corvalol” (“Corvalolum”) was used exclusively by one manufacturer as the name of the medicinal product. Information that Corvalol was manufactured by 70 pharmaceutical enterprises of the USSR is not true. In the middle of 20th century, Lomonosov Kyiv Chemical and Pharmaceuti...